Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: Results from a prospective, multicenter, phase II study

Haematologica

Volumn 95, Issue 11, 2010, Pages 1935-1942

  Kim, Seok Jin ^a   Lee, Jong Wook ^b   Jung, Chul Won ^a   Min, Chang Ki ^b   Cho, Bin ^b   Shin, Ho Jin ^c   Chung, Joo Seop ^c   Kim, Hawk ^d   Lee, Won Sik ^e   Joo, Young Don ^e   Yang, Deok Hwan ^f   Kook, Hoon ^f   Kang, Hyoung Jin ^g   Ahn, Hyo Seop ^g   Yoon, Sung Soo ^g   Sohn, Sang Kyun ^h   Min, Yoo Hong ⁱ   Min, Woo Sung ^b   Park, Hee Sook ^j   Won, Jong Ho ^j  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f Chonnam National University Medical School   (South Korea)

^g Seoul National University College of Medicine   (South Korea)

^h Kyungpook National University Hospital   (South Korea)

ⁱ Yonsei University College of Medicine   (South Korea)

^j Soonchunhyang University College of Medicine   (South Korea)

more..

Author keywords

Allogeneic stem cell transplantation; Chronic graft versus host disease; Quality of life; Rituximab; Steroid

Indexed keywords

AZATHIOPRINE; B CELL ACTIVATING FACTOR; CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG RESPONSE; DRUG TARGETING; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INFECTION; INFECTIOUS COMPLICATION; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RELAPSE; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CHILD; CHRONIC DISEASE; DIABETES MELLITUS; DRUG-INDUCED LIVER INJURY; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; STEROIDS; TRANSPLANTATION, HOMOLOGOUS; TUBERCULOSIS;

EID: 78149243861     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.026104     Document Type: Article

References (29)

1. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant. 2001;28(2):121-9.
2. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215-33.
3. Vogelsang GB. How I treat chronic graft-versus- host disease. Blood. 2001;97(5): 1196-201.
4. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100(1):48-51.
5. Arora M, Wagner JE, Davies SM, Blazar BR, Defor T, Enright H, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graftversus- host disease. Biol Blood Marrow Transplant. 2001;7(5):265-73.
6. Sutherland HJ, Fyles GM, Adams G, Hao Y, Lipton JH, Minden MD, et al. Quality of life following bone marrow transplantation: a comparison of patient reports with population norms. Bone Marrow Transplant. 1997;19(11):1129-36.
7. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005; 105(7):2973-8.
8. Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versushost disease with autoimmune manifestations. Blood. 2006;107(7):2993-3001.
9. Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007;13(20):6107-14.
10. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113(16):3865-74.
11. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and metaanalysis. Biol Blood Marrow Transplant. 2009;15(9):1005-13.
12. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9(8):505-11.
13. Mohty M, Marchetti N, El-Cheikh J, Faucher C, Furst S, Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant. 2008; 41(10):909-11.
14. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40(3):273-7.
15. Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G, et al. Anti- CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med. 2000;133(4):275-9.
16. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy- refractory chronic graft-versus-host disease. Blood. 2004;104(8):2603-6.
17. Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Takenaka H, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006;20(1):172-3.
18. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756-62.
19. Teshima T, Nagafuji K, Henzan H, Miyamura K, Takase K, Hidaka M, et al. Rituximab for the treatment of corticosteroid- refractory chronic graft-versus-host disease. Int J Hematol. 2009;90(2):253-60.
20. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2005;11(12):945-56.
21. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, et al. Measuring therapeutic response in chronic graft-versus- host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graftversus- Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12(3):252-66.
22. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute, 1994.
23. Simon R. How large should a phase II trial of a new drug be? Cancer Treat Rep. 1987;71(11):1079-85.
24. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 2006;54(1):192-201.
25. Kim SJ, Lee SJ, Choi IY, Park Y, Choi CW, Kim IS, et al. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. Eur J Haematol. 2008;81(3):177-84.
26. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354 (17):1813-26.
27. Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008;14(9 Suppl):8-15.
28. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114(1):7-19.
29. von Bonin M, Oelschlagel U, Radke J, Stewart M, Ehninger G, Bornhauser M, et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation. 2008;86(6):875-9.